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Background: Artemisia capillaris (AC) has been recognized as one of the promising candidates for
hepatoprotective, hypoglycemic, hypolipidemic, antiobesitic and anti-inflammatory therapeutic effectiveness. This
study evaluated the inherent mechanism and anti-apoptotic activity of 30% ethanol extract of AC (AC extract)
100 μg/ml on free fatty acids (FFAs)-induced HepG2 cellular steatosis and lipoapoptosis.
Methods: Hepatic steatosis was induced by culturing HepG2 cells with a FFAs mixture (oleic and palmitic acid at
the proportion of 2:1) for 24 h, thus ultimately giving rise to lipoapoptosis. Cell viability and lipid accumulation were
detected by MTT assay and Oil Red O staining method respectively and Caspase-3, −9, Bax, Bcl-2, p-JNK and PUMA
were measured for lipoapoptosis after 24 hours.
Results: AC extract significantly improved the FFAs-induced steatosis without cytotoxicity and Caspase-3, −9, Bax
and Bcl-2 were modulated profitably to HepG2 cells after AC treatment. In addition, AC extract inhibited the activation
of c-Jun NH2 terminal kinase (JNK) and PUMA, which mechanism is related to non-alcoholic steatohepatitis (NASH).
Conclusions: Combined together, AC extract exerted an obvious hypolipidemic and anti-apoptotic effect, indicating
that AC extract might have potential therapeutic herb against NASH.
Keywords: Artemisia capillaris (AC), HepG2, Non-alcoholic steatohepatitis (NASH), Lipoapoptosis, c-Jun NH2-terminal
kinase (JNK), p53 up-regulated mediator of apoptosis (PUMA)Background
The accumulation of fat in the liver is pathogenic if total
lipid exceeds more than 5% of liver weight or hepato-
cytes containing intracellular fat droplets are above 5%
[1]. Alcohol is one of well-known causes for this higher
intrahepatic fat content called fatty liver. In recent times,
however, non-alcoholic fatty liver disease (NAFLD) with-
out excessive drinking of alcohol (<20 g/d for female
and 30 g/d for male) draws public attention [2].
The prevalence of NAFLD is estimated to be about 34%
among adults in the United States [3] and it is recognized
as the primary cause of liver dysfunction in children [4].
Concerning this common liver disease, it encompasses a
variety of hepatic features from simple fat deposition to
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unless otherwise stated.cirrhosis and hepatocellular carcinoma (HCC). About
10% of benign steatosis will develop into more severe
NASH [5], which indicates the characteristic increase
of inflammatory and apoptotic cells in the liver, and
may result in cirrhosis up to 25% [6]. In addition,
NASH was reported to be the third commonplace dis-
ease to which liver transplantation is efficacious [7] and
patients with NASH exhibit substantially high mortality in
cardiovascular diseases [8]. Nevertheless, the current med-
ical world has no validated treatment for NASH [9].
There are various tools that may explain the pathogen-
esis and progress of NASH: endoplasmic reticulum (ER)
stress, oxidative stress, inflammatory factors, insulin re-
sistance, and so on. These days, however, increasing evi-
dence suggests that ectopic fat incretion in liver triggers
lipoapoptosis [10], a potential underlying mechanism in-
volved in apoptosis in NASH [11], which is shown in
NASH liver cell under free fatty acids (FFAs) overload
[12]. Thus, lipoapoptosis is a distinguishable character ind. This is an Open Access article distributed under the terms of the Creative
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able in NASH than simple steatosis [13] and alcoholic
steatohepatitis [12]. For this programmed cell death
by excess lipid deposition in NASH, a lot of reports
have expressed c-Jun NH2terminal kinase (JNK) as a
potential modulator activating apoptotic effectors such as
p-53-up-regulated mediator of apoptosis (PUMA), Bax,
Caspase-3 and −9. In other words, JNK activation by FFAs
can induce mitochondrial apoptotic pathway by increasing
PUMA expression which modulates the pro-and anti-
apoptotic proteins such as Bax and Bcl-2 [14]. Judging
from this lipoapoptotic pathway, PUMA and JNK could
be specific targets for treatment of NASH.
Artemisia Capillaris (AC), which is included in the
family of Asteraceae and belongs to the plant genus Ar-
temisia, is an indigenous medicinal herb widely used as
hepatoprotective, analgesic, and antipyretic drug [15]. As
metabolic syndromes, such as dyslipidemia, hypergly-
cemia, obesity and cardiovascular disease have been major
public health problem, relevant approaches to the thera-
peutic activities of AC are noteworthy. For example, AC
has anti-diabetic and lipid-lowering effects in hypergly-
cemic patients [16] and dyslipidemic rodents [17] as well
as HepG2 cell incubated with 1 mM palmitic acid (PA)
[18] respectively and AC ethyl acetate fraction decreased
the accumulation of body fat by suppressing PPAR γ in
adipocytes [19]. Furthermore, AC contributed to anti-
fibrotic [20], anti-oxidant [21] and anti-inflammatory [22]
effects involved in the pathological feature of NASH.
Despite this therapeutic suggestion of AC for NASH,
there have not been yet extensive studies that explain
medical connection between AC and NASH in respect
of JNK and PUMA. In this regard, this study was de-
signed to examine the anti-steatotic and anti-apoptotic
effects of 30% ethanol extract of AC (AC extract) on
HepG2 cells induced by FFAs 1 mM to show the effect-
iveness for NASH. We measured the PUMA down-
regulatory effect of AC extract and tried to investigate
the inhibitory effect of AC extract on JNK signaling
linked to PUMA, a key pathway relevant to lipoapopto-
sis. Furthermore, the result from this NASH model will
contribute to developing a potential therapy for human
NASH.
Methods
Preparation of AC extract
AC was purchased from Kyung Hee Oriental Herbal
Medicine Research Center (Seoul, South Korea). The
herb was cut down in a proper size, and extracted as fol-
low. Above all, 30% EtOH was added to AC 100 g and
then 2 times extracted repeatedly for 3 h at 40°C using
extractor (JAC-4020, KODO Technical Research Co.,
Ltd., Hwaseong, South Korea). After vacuum evapor-
ation (N-1000S-WD, Eyela Co., Tokyo, Japan) of thissample, it was dissolved with 30% EtOH 100 ml at 4°C
for 24 h. And then, supernatant liquid of the solvent was
freeze-dried (FDU-1100, Eyela Co., Tokyo, Japan) after
one more vacuum evaporation, thereby yielding the 30%
ethanol extract of AC (AC extract) [23].
HepG2 cell culture
Fully differentiated human hepatoblastoma cell line,
HepG2 cells were purchased from the Korean Cell Line
Bank (KCLB®, Seoul, South Korea). HepG2 cells were
grown for suspension culture at 37ºC in an atmosphere of
5% CO2 in a Dulbecco's Modified Eagle Medium (DMEM)
containing 4.5 g/L of glucose (Lonza, Walkersville,
MD) supplemented with 10% fetal bovine serum (FBS;
Lonza, Walkersville, MD) and antibiotics antimycotics
(Sigma-Aldrich, St. Louis, MO).
Cell viability assay
MTT (3-(4,5-dimethythiazol-. 2-yl)-2,5-diphenyl tetrazo-
lium bromide) was purchased from Invitrogen (Carlsbad,
CA). Before treatment, it was dissolved as a 1 mg/ml
stock in phosphate-buffered saline (PBS). HepG2 cells
were seeded at a density of 1.5 × 103 cells/well in 96-well
plate and incubated for 48 h. The cells were treated with
disparate concentrations of AC extract (100, 500 and
1000 μg/ml) for 24 h and FFAs 1 mM in another group
for 1 h and 24 h, respectively. And then, 100 μl of MTT
solution were treated for 2 h. After 4 h, MTT solution
was removed by aspiration, the insoluble formazan crys-
tals were dissolved in DMSO and measured the absorb-
ance was read at 570 nm with a Bio-Rad model 680
microplate reader (Bio-Rad, Hercules, CA).
FFAs and AC extract treatment
Oleic acid (OA) and PA were purchased from Sigma-
Aldrich (St. Louis, MO). OA and PA were dissolved in
isopropanol at the concentration of 50 mM stock solu-
tion. DMEM containing 1% bovine serum albumin
(BSA; Lonza, Walkersville, MD) was used in this ex-
periment. Final concentration of the both fatty acids
was 50 μM. After starvation with DMEM containing
low glucose for 24 h, FFAs 1 mM (OA 0.66 mM and
PA 0.33 mM) were treated for 24 h. After treatment of
FFAs, AC was treated at the concentration of 100 μg/ml
for 24 h.
Oil Red O staining
Oil Red O solution was purchased from Sigma-aldrich.
Oil Red O staining was performed according to the ref-
erence [24,25]. To stain adipocytes, cells were washed
three times with PBS to remove unbound staining and
fixed with 10% formalin for 1 h. After washing for three
times with distilled water, cells were washed with 60%
isopropanol briefly and incubated with 60% filtered Oil
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30 min at room temperature. Cells were washed with
water briefly and then stained with hematoxylin (Sigma-
Aldrich, USA). For quantitative analysis of Oil Red O con-
tents levels, isopropanol was added to each samples and
then shaken at room temperature for 5 min. The ab-
sorbance was read at 510 nm with a Bio-Rad model
680 microplate reader.
Western blot analysis
The cells were washed and scraped with PBS, and incu-
bated in an RIPA buffer containing a protease inhibitor
cocktail (Roche Diagnostics, Mannheim, Germany). After
protein preparation, Bradford assay was performed. The
same amounts of total protein (20 μg) were resolved in
12% sodium dodecyl sulfate (SDS)-acrylamide gel and
transferred to the PVDF membrane. The following pri-
mary antibodies were used: PUMA, JNK, p- JNK,
Caspase-3, −9, Bax and Bcl-2 1:3000 in 2% BSA (Cell
signaling, Danvers, MA). β-actin (Santa Cruz Biotechnology,
Inc., Dallas, TX) was used as the internal control. Membrane
was incubated with the secondary antibody (1:10,000 dilu-
tion); the blot was detected with an ECL solution (EMD
Millipore Corporation, Billerica, MA) using a Davinch-
Chemi™ chemiluminescence imaging system (Davinch-K,
Seoul, South Korea).
Real-time quantitative PCR analysis
Total RNA was isolated from HepG2 cells using a
Hybrid-R kit (GeneAll, Seoul, South Korea). Following
that, the cDNA was hybridized from 1 μg of the total
RNA with a LeGene 1st strand cDNA synthesis system
(LeGene Bioscience, San Diego, CA). BBC3 (PUMA)
mRNA expression level was determined by a quantita-
tive PCR as described in the manufacturer’s protocol
(Life Technologies, Grand Island, NY). To analyze the
results, 2-ΔΔCt values compared to the normal sample
were determined with StepOne software (Life Technolo-
gies, Grand Island, NY). GAPDH was used as an en-
dogenous control. The sequences of the forward and
reverse primer were 5′-CATGGCCTTCCGTGTTCCT
A-3′ and 5′-GCGGCACGTCAGATCCA-3′ for the
GAPDH gene, 5′- GACGACCTCAAC GCACAGTA-3′
and 5′- AGGAGTCCCATGATGAGATTGT-3′ for the
PUMA gene, respectively [26,27].
Statistical analysis
All data represent at least two separate experiments
and each experiment was performed in triplicate. The
significance of the data was analyzed with Prism 5
software with one-way ANOVA and Bonferroni’s post-
hoc test to compare each set of data. Bars show the
means ± SEMs. *, p < 0.05; **, p < 0.01; ***, p < 0.001.Results
Effects of FFAs and AC extract on cell viability
To determine whether the treatment of AC extract on
HepG2 cells has value for medical use with no toxic ef-
fect, the cells were treated with different concentrations
of AC extract (100, 500 and 1000 μg/ml) for 24 h and
cell viability was evaluated by MTT assay. Both 500
and 1000 μg/ml of AC extract were significantly toxic
to HepG2 cells which viability was reduced up to
about 60% (p < 0.001). In contrast, 100 μg/ml of AC
extract showed no substantial decrease in cell viability
(Figure 1A). And we determined the LD50 of the AC
extract on HepG2 cells. AC extract was treated with
15-different concentrations on HepG2 cells for 24 h,
and the LD50 was calculated. The LD50 was 1866 μg/ml
(Figure 1B).
As compared to AC extract, after treating HepG2 cells
with FFAs 1 mM for 24 h, this lipid overload induced in-
comparably detrimental effect on cell viability. The num-
ber of viable cells significantly decreased to less than
50% in a time-dependent manner (p < 0.001) (Figure 1C).
These data indicate that HepG2 cells undergo significant
lipotoxic change under FFAs 1 mM for 24 h with about
50% decreased amount of viable cells as compared to
the safety of AC extract treatment and the cells overex-
posed to FFAs could be in vitro model of hepatic
lipoapoptosis.
Effect of AC extract on steatosis
In order to observe hepatic lipid accumulation, HepG2
cells were exposed to FFAs 1 mM, the mixture with two
fatty acids which co-incubation can lead to steatogenesis
and apoptosis simultaneously in hepatocytes. In other
words, this FFAs organization with OA and PA 2:1 en-
ables fat contents to be maximized and minimizes cellu-
lar damage induced by lipid overload tolerating some
degree of apoptosis [25]. After culturing with FFAs
1 mM for 24 h in media containing 1% BSA, HepG2
cells were stained with Oil Red O solution for 30 min at
room temperature, and then the increased intracellular
lipid contents dyed pink were visually observed by
microscope (×400) (Figure 2B). This lipid deposition
stained by Oil Red O was analyzed quantitatively and a
bar graph to display the results confirmed the visible
lipid incretion versus only 1% BSA to be statistically sig-
nificant (p < 0.001). In this FFAs-induced steatosis in
HepG2 cells, the high buildup of lipid droplets was ame-
liorated to their almost original condition after treat-
ment of AC extract for 24 h (Figure 2C and D).
Steatosis is one of hallmark properties of patients with
NASH [28]. Accordingly, the significantly reduced cellu-
lar lipid level in AC extract-treated group could show
the potential for the development of appropriate treat-
ments for NASH.
Figure 1 Cell viability assay. After treatment of AC extract and FFAs 1 mM on the HepG2 cells, MTT assay was performed. AC extract was
treated as 100, 500 and 1000 μg/ml for 24 h. AC 100 μg/ml showed no toxicity to HepG2 cells (A). Differently concentrated AC extracts were
treated on HepG2 cells for 24 h and the LD50 was calculated (B). FFAs were treated at 1 mM concentration for 1 h or 24 h. The treatment of
FFAs showed significant toxicity to HepG2 cells for both 1 h or 24 h (C). Statistical significance was determined by one-way ANOVA and the
values are mean ± SEM. **, p < 0.01; ***, p < 0.001.
Figure 2 Oil Red O staining for HepG2 cells and quantitative analysis of lipid. FFAs 1 mM for 24 h induced lipid accumulation in HepG2
cells. Visual observation of lipid content was captured by microscope (×400): the control cells treated with only 1% BSA (A), cells treated with
FFAs 1 mM for 24 h (B), and cells pretreated with FFAs 1 mM for 24 h and then cultured with AC extract for 24 h (C). The quantitative analysis of
cellular steatosis (D) was measured through deposited Oil Red O in the cells. Statistical significance was determined by one-way ANOVA and the
values are mean ± SEM. ###, p < 0.001, control versus FFAs-treated group (lipoapoptosis-induced group) and ***, p < 0.001, FFAs-treated group
(lipoapoptosis-induced group) versus AC extract treated group.
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Since the increase in pJNK expression is a principal
characteristic in HepG2 cells under lipid overburden
[14] and JNK is triggered in the liver tissue of NASH pa-
tients [27], the regulation of pJNK might open the thera-
peutic way for NASH, a chronic liver disease. Based on
western blot using primary antibody for pJNK, treatment
on HepG2 cells with total FFAs 1 mM for 24 h evidently
amplified the pJNK expression level (Figure 3A). This re-
sult is consistent with the previous studies in which JNK
activation contributes to the lipoapoptosis observed in
lipogenic hepatocyte damage [14]. Compared with the
FFAs-treated group, AC extract exposure following pre-
treatment with FFAs 1 mM generated a conspicuous de-
crease in pJNK activity, which had been augmented byFigure 3 pJNK and PUMA expression level. Total cell lysates were
prepared from control cells, cells treated with FFAs 1 mM for 24 h,
and cells pretreated with FFAs 1 mM for 24 h and then cultured with
AC extract for 24 h respectively. (A) The overexpressed level of pJNK and
PUMA were down-regulated after treatment of AC extract for 24 h.
(B) PUMA expression level normalized with β-actin was measured
by densitometry analysis and represented as bar charts. β-actin
was used as an internal control. Statistical significance was determined
by one-way ANOVA and the values are mean ± SEM. ###, p < 0.001,
control versus FFAs-treated group (lipoapoptosis-induced group)
and ***, p < 0.001, FFAs-treated group versus AC extract treated group.FFAs for 24 h (Figure 3A). As a consequence of this, the
post-treated AC induced inhibitory effect on JNK phos-
phorylation which hampers lipid metabolism and de-
velops into NASH. In other words, the presence of AC
extract disturbed JNK-mediated pathway in hepatocyte
during lipoapoptosis and JNK-dependent cascade can be
a hypothesized pathway to explain the mechanism
through which AC extract contributes to the improve-
ment of FFA-mediated lipoapoptosis in HepG2 cells.
Effect of AC extract on PUMA activation
FFAs could cause cellular injury through JNK-potentiated
route which mechanism is complicated. The possible lead-
ing pathway of this lipoapoptotic procedure is intimately
correlated with a series of sequence from pJNK to proa-
poptotic proteins. PUMA, a pro-apoptotic protein, is up-
regulated via JNK phosphorylation and then stimulates
Bax [27], which leads to mitochondrial apoptotic response
depending on caspase activity [29]. In particular, PUMA
expression is highly related to FFAs-overloaded lipoapop-
tosis in hepatic cells [27]. Actually, PUMA mRNA and
protein levels increased significantly over the control
group at 24 h after FFAs 1 mM treatment in HepG2 cells
(Figures 3 and 4). Interestingly, the 100 μg/ml of AC ex-
tract at which dosage hepatic steatosis had been effectively
improved (Figure 2), also attenuated the increased PUMA
as well as pJNK (Figures 3 and 4). These data suggest that
AC extract might regulate PUMA transcription in hepatic
lipoapoptosis and play an inhibitory role in an apoptotic
axis associating with JNK and PUMA.Figure 4 PUMA mRNA expression level. PUMA mRNA was
prepared from control cells, cells treated with FFAs 1 mM for 24 h,
and cells pretreated with FFAs 1 mM for 24 h and then cultured
with AC extract for 24 h, respectively. Data were normalized with
GADPH level. Statistical significance was determined by one-way
ANOVA and the values are mean ± SEM. ###, p < 0.001, control versus
FFAs-treated group (lipoapoptosis-induced group) and ***, p < 0.001,
FFAs-treated group versus AC extract treated group.
Figure 5 Bax, Bcl-2, Caspase-9, and −3 expression level. Bax and
Caspase-3 were activated while Bcl-2 and Caspase-9 were suppressed
conspicuously after FFAs 1 mM treatment in HepG2 cells. But, AC
extract treatment for 24 h reduced the expression level of Bax
and Caspase-3, and augmented the Bcl-2 and Caspase-9 manifestation
(A). In a bar graph, AC treatment suppressed the Bax/Bcl-2 expression
level which had been significantly increased after induction of
lipoapoptosis (B). The cleaved forms of Caspase-3 and Caspase-9
were down-regulated after treatment of AC extract (A). Statistical
significance was determined by one-way ANOVA and the values
are mean ± SEM. ###, p < 0.001, control versus FFAs-treated group
(lipoapoptosis-induced group) and ***, p < 0.001, FFAs-treated
group versus AC extract treated group.
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The activation of PUMA proteins under lipotoxic situ-
ation was known to suppress Bcl-2, an anti-apoptotic pro-
tein, and function to release cytochrome c from the
mitochondria into the cytosol, thereby activating Caspase-
3 and −9 [30] and PA-induced PUMA expression en-
hanced Bax activation in lipoapoptosis [27]. In addition,
Bax activation and lipoapoptosis depend on JNK down-
stream [31]. To confirm the effect of AC extract on
HepG2 cells depending on this sequential process in lipoa-
poptosis, Bax, Bcl-2, Caspase-3 and −9 were finally ana-
lyzed by western blotting method in this experimental
model. After HepG2 cells were overexposed to FFAs
1 mM for 24 h, Bax, Caspase-3 and −9 activations were
observed as anticipated (Figure 5A). In particular, Bax/
Bcl-2 ratio reached an about 7-fold increment as com-
pared to the control group (Figure 5B). Following AC ex-
tract treatment for 24 h after inducing lipoapoptosis in
HepG2 cells, western blot analysis showed that AC extract
significantly blocked considerable cellular death by
inhibiting activation of Bax and catalytic cleavage of
Caspase-3 and −9 (Figure 5A). Taken together, lipoa-
poptosis induced by FFAs 1 mM in HepG2 cells under-
goes the mitochondrial pathway involved in the activation
of apoptotic executors as Bax, Caspase-3 and −9 and AC
treatment might be revealed to be efficient in restoring
hepatic injury.
Discussion
The adipocyte has the effective function which disposes
large amounts of FFAs. However, most other cells ex-
perience the harmful impairment, referred to as lipoa-
poptosis, under the FFAs overload. In other words, lipid
surplus in non-adipose tissue produces detrimental
change, thereby eventually leading to cellular damage
and death [32]. In case of hepatocytes, fat-laden liver
cells overloaded with FFAs may bring about severe fatty
hepatitis, a metabolic syndrome called NASH. A patho-
genesis of this NASH is as follows. Originally, as the
moderate amount of circulating FFAs enters liver cells,
these FFAs were changed to detoxified neutral triglycer-
ides [27]. However, the patients with NASH show more
elevated circulating FFAs than NAFLD people [33]. This
high non-esterified circulating FFAs concentration in
NASH may aggravate the toxicity and lipoapoptosis to
liver.
To make the closest in vitro model to hepatocellular
lipoapoptosis in NASH, HepG2 cells and FFAs 1 mM
were applied in this present study. Although human
hepatic cells like L-02 (Chu, Wang et al. 2011), LX-1
and LX-2 [34] seem to be strictly representative of hu-
man liver, there are some barriers such as difficulty in
reproducing [35]. On the other hand, HepG2 or Huh-7
cells are easily available with numerous replications butcan lead to instable genetic and epigenetic modification.
[36]. In particular, HepG2 cells, a well differentiated hu-
man hepatoblastoma cell line, are widely used because
they can express various functions related to liver [37].
In addition, both FFAs-overloaded human hepatocytes
and HepG2 cells exhibited comparable levels of intracel-
lular lipid contents, which were nearly similar to lipid
accumulation of the hepatocytes obtained from human
steatotic liver [38]. Accordingly, HepG2 cells could be
reliable alternative cell lines to make the realistic NASH
experimental model.
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normal subjects and NAFLD patients [39]. Steatosis ex-
tent was larger when cells were treated with OA than
PA and the cellular susceptibility and toxicity to lipid is
more severe in PA than OA [25]. In this context, an ap-
propriate mixing ratio of PA and OA can lead to signifi-
cant lipid intracellular accumulation and lipoapoptosis,
but just minimizing cellular damage. In one recent
study, FFAs 1 mM consisted of OA and PA 2:1 maxi-
mized fat accumulation without severe cellular toxicity
[38]. Given this information, OA 0.66 mM and PA
0.33 mM were used in the present study because this
combination proportion seems to be more efficient to
induce lipoapoptosis in HepG2 cells than when used
individually.
In this in vitro model of lipoapoptosis, we investigated
whether AC extract alleviates FFAs-induced lipoapopto-
sis in HepG2 cells. Since in vitro model comfortably en-
ables us to know the molecular pathway and curative
power of drugs even though the remodeling of delicate
human organ is difficult because of its rather simplicity
[35], the current study is helpful for us to understand
anti-steatic and anti-apoptotic effects of AC extract in
respect of molecular mechanism.
It is preferential to elicit how a molecular pathway mod-
ulates the pathogenesis and progression of NASH for
therapeutic use of AC extract. There are a large number
of molecular algorithms which have been hypothesized to
explain the lipid-mediated apoptosis: the extrinsic path-
way associated with Fas ligand or tumor necrosis factor
receptor and the mitochondrial-mediated intrinsic path-
way [25]. According to the current studies, activation of
JNK, a stress-stimulated member of mitogen-activated
protein kinase (MAPK) family, has been regarded as
the most probable pro-apoptotic mechanism in lipid-
mediated apoptosis. For example, lysophosphatidylcho-
line treatment resulted in a robust activation of JNK
[40] and JNK modulated Bax activation under cellular
toxicity induced by saturated fatty acids [14]. In addition,
JNK is well expressed in the liver stressed by lipid. JNK is
activated in human NASH as well as murine models of
steatohepatitis [41,42]. Moreover, JNK inhibitors abrogate
lipoapoptosis in both human and mouse hepatic cell lines
[14]. Therefore, lipoapoptosis in liver cell line has been
linked to induction of JNK and pJNK is highly expressed
after FFAs 1 mM treatment on HepG2 cells. Interestingly,
stimulation of JNK influences on the subsequent increase
in PUMA and both JNK and PUMA expression are closely
related to lipid overload of the NASH people [27]. PUMA,
p53 inducible gene, is closely related to strong apoptosis
and modulates anti-apoptotic Bcl-2 and pro-apoptotic
Bax, thereby activating caspase-3 and −9 [30]. In addition,
it has been reported that PUMA over-activation is associ-
ated with p53-dependent lipoapoptosis in mitochondria[43]. Furthermore, the progress of apoptosis continues at
a rapid pace within hours after PUMA expression [44].
In this connection, we focused our study on the rela-
tion between AC extract treatment and PUMA and it
may be summarized as follows. AC extract treatment
(100 μg/ml) significantly lowered PUMA mRNA and
protein levels as well as pJNK (Figures 3 and 4). This is
a novel finding that shows the junction of PUMA and
AC extract in NASH in vitro model, powerfully suggest-
ing the therapeutic potential of AC extract on NASH.
There are two major lipid-lowering and anti-apoptotic
action in AC extract on excess FFAs in HepG2 cells.
First, treatment of AC extract considerably decreased ac-
cumulation of lipid droplets in HepG2 cells, not affect-
ing their viability. Although buildup of lipid to some
degree, especially in case of oleic acids, protects the cells
from lipotoxicity [25], the lipid-reducing operation of
AC extract in this study might be explained as cytopro-
tective and antiapoptotic effects because this FFAs sur-
plus is accompanied by apparent apoptosis, which
executors like Bax and Caspase were highly identified
by Western blotting analysis (Figure 5). Secondly, we
confirmed that AC extract treatment recovered the
FFAs-induced Bax, caspase, PUMA and pJNK, suggest-
ing that AC extract influences on mitochondrial apop-
totic pathway (Figure 3). There is little information on
medicinal drugs which have down-regulatory effect on
PUMA in relation to NASH. Additionally, the function
of AC extract on PUMA and pJNK in lipid-induced
liver cells has not been studied yet.
Conclusions
In conclusion, AC extract (100 μg/ml) alleviated hepatic
steatosis induced by the accumulation of FFAs 1 mM in
HepG2 cells, indicating that it promoted the ability of
disposing lipid and blocked hepatic lipid pile, and de-
creased pJNK, PUMA, Bax and caspase relevant to
apoptosis. Based on this intriguing finding, PUMA and
pJNK might give molecular hint on developing AC ex-
tract as validated regimen against NASH. Even though
there are some limitations like the use of HepG2 cells,
not human liver cells, and no data on the pre-treatment
of AC extract for cytoprotective effects and comparison
with Vitamin E [45] or antidiabetic metformin [46] pos-
sible as a potential treatment for NASH, our study would
give an applicable idea useful to therapeutic strategies of
AC extract in NASH. This current study suggests that AC
extract might be a candidate treatment for further research
in in vivo NASH model, thereby providing some critical in-
formation that enables to understand the progression of
steatohepatitis toward cirrhosis and liver cancer.
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